CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors

Saygin, Caner; Wiechert, Andrew; Rao, Vinay S.; Alluri, Ravi Kumar; Connor, Elizabeth V.; Thiagarajan, P. S.; Hale, James S.; Li, Yan; Chumakova, Anastasia; Jarrar, Awad; Parker, Yvonne; Lindner, Daniel J.; Nagaraj, Anil Belur; Kim, Julie; DiFeo, Analisa; Abdul‐Karim, Fadi W.; Michener, Chad M.; Rose, Peter G.; Debernardo, Robert; Mahdi, Haider; McCrae, Keith R.; Lin, Feng; Lathia, Justin D.; Reizes, Ofer

doi:10.1084/jem.20170438

Cited by 85 publications

(118 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such modulatory effects of JNK on responses to chemotherapies and targeted therapies were also observed in gastric cancer [86], hepatocellular carcinoma [87], head and neck cancer [88], endometrial cancer [89], and ovarian cancer [90]. An interesting finding in this context is that JNK signaling seems specifically important for the maintenance of cancer stem cells in different cancer types including pancreatic [91], endometrial [92], and ovarian cancer [93]. In ovarian cancer, the mechanism involves upregulation of survivin, an antiapoptotic protein that protects stem cell viability [94].…”

Section: Jnk Enhancing Resistance To Erk Pathway Inhibitors and Chemomentioning

confidence: 83%

Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity

Lee

Rauch

Kölch

2020

IJMS

523

338

View full text Add to dashboard Cite

Mitogen-activated protein kinase (MAPK) pathways represent ubiquitous signal transduction pathways that regulate all aspects of life and are frequently altered in disease. Here, we focus on the role of MAPK pathways in modulating drug sensitivity and resistance in cancer. We briefly discuss new findings in the extracellular signaling-regulated kinase (ERK) pathway, but mainly focus on the mechanisms how stress activated MAPK pathways, such as p38 MAPK and the Jun N-terminal kinases (JNK), impact the response of cancer cells to chemotherapies and targeted therapies. In this context, we also discuss the role of metabolic and epigenetic aberrations and new therapeutic opportunities arising from these changes.

show abstract

Section: Jnk Enhancing Resistance To Erk Pathway Inhibitors and Chemomentioning

confidence: 83%

Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity

Lee

Rauch

Kölch

2020

IJMS

523

338

View full text Add to dashboard Cite

show abstract

“…The clinical outcome of dystrophic scoliosis patients treated with posterior-only fusion by using hooks and rods demonstrated that the pseudarthrosis rate was high and curve progression was common [17]. Recently, some good results of posterior only fusion surgeries in NF-1 patients with dystrophic scoliosis have been reported [9,10,19]. In this study, we reported our results about the posterior only fusion procedure in NF-1 patients with EOS.…”

Section: Discussionmentioning

confidence: 88%

“…There was no neurological complication (transient or permanent neurological deficiency) observed. Given the facts that the complication rate of anterior-posterior approach is as high as 64%, the probability of perioperative pulmonary dysplasia is as high as 45%, and the fact that lung injury and dural tear are also seen during the precedure [19,20], we suggest that posterior fusion surgery be a good alternative way to get a better postoperative outcome and reduce the postoperative complications.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Posterior only instrumented fusion provides incomplete curve control for early-onset scoliosis in type 1 neurofibromatosis

Cai

Qiu

et al. 2020

BMC Pediatr

View full text Add to dashboard Cite

Background: The mid-long term outcomes of posterior spinal fusion in pediatric neurofibromatosis type 1 (NF-1) patients are rarely reported, so does the effectiveness of itsorthopeidc maintenance function. This study aims to evaluate the mid-long term surgical outcomes of posterior only instrumented spinal fusion for early-onset scoliosis (EOS) in NF-1 patients. Methods: A retrospective review was performed on a cohort of 10 NF-1 patients having EOS from 2008 to 2014 in our hospital, the age averaged at 7.8 years old when they underwent posterior only instrumented spinal fusion for their EOS. Both general clinical data and surgical specific data of the patients were collected and reviewed, and the dystrophic progression of EOS was evaluated during the follow-up. Results: The average duration of follow-up was 54 months (24 to 88 months). All patients underwent posterior only instrumented spinal fusion at 1 stage. The primary curves of EOS were thoracic in 9 cases and 1 patient had lumbar scoliosis. Preoperative major curve was significantly corrected (from 66.1 to 31.1 degrees). However, the major curve deteriorated significantly to 40.1 degrees on average at the end of the follow-up. The T1-S1 distance increased 2.8 cm on average and kept increasing at a rate of 0.6 cm/year during the follow-up. Conclusions: Posterior only fusion surgery was not a good option to treat the EOS in NF-1 patients despite the relatively short segments involvement in the disease. The maintenance of orthopedic effect after treatment was not satisfactory.

show abstract

“…At the most recent, a study pointed that cancer stem cells are responsible for cancer proliferation and chemoresistance [20], it was found that SPARC-related modular calcium binding 2 (SMOC-2) drive the endometrial cancer chemoresistance functional as a endometrial cancer stem cell molecule. Similarly, Caner Saygin et.al reported that CD55, as unique signaling node, drives self-renewal and chemoresistance in endometrioid cancers [29]. Other study found that autophagy also involves in chemoresistance [30].…”

Section: Discussionmentioning

confidence: 91%

Stigmasterol Sensitizes Endometrial Cancer Cells to Chemotherapy By repressing Nrf2 Signal Pathway

Liao

Zhu

Bai

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Chemoresistance reduces the 5-year survival rate of endometrial cancer patient, which is the current major obstacle for cancer therapy. Increasing evidence state that Nrf2 contributes to chemoresistance in several kinds of cancer. However, its role in endometrial cancer cells remains unclarified. Methods: Immunohistochemistry staining was used to detect the expression of Nrf2 in normal patient and endometrial cancer patient. Stable transfection Ishikawa cell line with high level of Nrf2 was established to evaluate its role in chemoresistance. Dot blot assays were used to assess global hydroxymethylation level after stigmasterol treatment. Cellular growth profile was detected by CCK8 assay. Western blot was used to evaluate the changes of the target molecules after various treatments. Results: Nrf2 is overexpressed in endometrial cancer tissues compared with the normal endometrium. Overexpression of Nrf2 resulted in decrease sensitivity to cisplatin. In addition, stigmasterol has been identified as a novel Nrf2 inhibitor. It enhanced the sensitivity of endometrial cancer cells to cisplatin, and the underlying mechanism is that stigmasterol declines the Nrf2 protein level. Conclusions: Our findings identified stigmasterol as a new potential inhibitor of Nrf2 and highlight a critical role of stigmasterol in overcoming chemoresistance in endometrial cancer therapy.

show abstract

CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors

Cited by 85 publications

References 34 publications

Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity

Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity

Posterior only instrumented fusion provides incomplete curve control for early-onset scoliosis in type 1 neurofibromatosis

Stigmasterol Sensitizes Endometrial Cancer Cells to Chemotherapy By repressing Nrf2 Signal Pathway

Contact Info

Product

Resources

About